Literature DB >> 21762749

Seroepidemiological study of pandemic influenza H1N1 following the 2009-2010 wave in Greece.

Helena C Maltezou1, Panagiotis Katerelos, Maria Mavrouli, Athanasia Lourida, John G Routsias, Nicholas Spanakis, Antonios Maragos, Anastasia Tedoma, Yiannis Bassiakos, Georgios Koratzanis, Stephanos Mantagos, Simeon Metallidis, Aspasia Katragkou, Pavlos Nikolaidis, Emmanuel Roilides, Maria Theodoridou, Athanassios Tsakris.   

Abstract

Knowledge of seroprevalence rates against 2009 pandemic H1N1 virus will assist vaccination recommendations and the preparation of the health-care system during subsequent years. This study was conducted in Greece during June-August 2010 to estimate the seroprevalence rate against pandemic H1N1 virus. Persons presenting in 29 health-care facilities across the country were studied. Seroprevalence was estimated employing a virus-free ELISA that specifically recognizes 2009 H1N1 virus antibodies in human sera. Sera collected from 2005 to April 2009 were also used to estimate pre-pandemic seroprevalence rates. A total of 954 persons were studied. The overall seroprevalence rate was 28.5% (95% confidence interval=25.6-31.3%). Age-specific rates were 34.2% in persons 0-4 years, 36.3% in persons 5-19 years, 25.0% in persons 20-39 years, 23.4% in persons 40-59 years, and 31.8% in persons ≥ 60 years. The highest rates were recorded in the Regions of Ionian Islands (67%) and Epirus (42.9%), while the lowest (8.4%) in the Region of Thessaly. Age-specific attack rates of infection during 2009-2010 were 28.8% in persons 0-4 years, 32.5% in persons 5-19 years, 14.3% in persons 20-39 years, 19.1% in persons 40-59 years, and 14.4% in persons ≥ 60 years. Multivariate analysis revealed that Region of residence and caring for children <5 years were associated with increased risk for seropositivity. Urbanity, personal and family characteristics, working in a health-care facility or in a school, history of pandemic H1N1 vaccination or history of influenza-like illness during 2009-2010 were not associated with increased risk for seropositivity.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762749     DOI: 10.1016/j.vaccine.2011.06.098

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Pandemic influenza A/H1N1pdm in Italy: age, risk and population susceptibility.

Authors:  Stefano Merler; Marco Ajelli; Barbara Camilloni; Simona Puzelli; Antonino Bella; Maria Cristina Rota; Alberto Eugenio Tozzi; Maurizio Muraca; Marcello Meledandri; Anna Maria Iorio; Isabella Donatelli; Caterina Rizzo
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

2.  A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.

Authors:  Helena C Maltezou; Bettina Krumbholz; Maria Mavrouli; Maria Tseroni; Maria N Gamaletsou; Evanthia Botsa; Cleo Anastassopoulou; Aristofanis Gikas; Evanthia Fournarakou; Maria Kavieri; Aikaterini Koureli; Dionysia Mandilara; Aikaterini Marinopoulou; Argyro Theodorikakou; Panagiotis Tsiahris; Anastasia Zarzali; Spyridon Pournaras; Athanasia Lourida; Ioannis Elefsiniotis; Georgia Vrioni; Nikolaos V Sipsas; Athanasios Tsakris
Journal:  J Med Virol       Date:  2021-12-04       Impact factor: 2.327

3.  Estimation of the burden of pandemic(H1N1)2009 in developing countries: experience from a tertiary care center in South India.

Authors:  Mahesh Moorthy; Prasanna Samuel; John Victor Peter; Saranya Vijayakumar; Dipika Sekhar; Valsan P Verghese; Indira Agarwal; Prabhakar D Moses; Kala Ebenezer; Ooriapadickal Cherian Abraham; Kurien Thomas; Prasad Mathews; Akhilesh C Mishra; Renu Lal; Jayaprakash Muliyil; Asha Mary Abraham
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

4.  Pandemic influenza A(H1N1)pdm09 seroprevalence in Sweden before and after the pandemic and the vaccination campaign in 2009.

Authors:  Andreas Mörner; Andreas Bråve; Anna-Maria Kling; Sharon Kühlmann-Berenzon; Katarina Krook; Mona Hedenskog; Irene Silhammar; Margaretha Ljungman; Ake Ortqvist; Sören Andersson; Maria Brytting; Rigmor Thorstensson; Annika Linde
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

5.  2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos.

Authors:  Alexia Kieffer; Phimpha Paboriboune; Pascal Crépey; Bruno Flaissier; Vimalay Souvong; Nicolas Steenkeste; Nicolas Salez; François-Xavier Babin; Christophe Longuet; Fabrice Carrat; Antoine Flahault; Xavier de Lamballerie
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

6.  Personal decision-making criteria related to seasonal and pandemic A(H1N1) influenza-vaccination acceptance among French healthcare workers.

Authors:  Lila Bouadma; François Barbier; Lucie Biard; Marina Esposito-Farèse; Bertrand Le Corre; Annick Macrez; Laurence Salomon; Christine Bonnal; Caroline Zanker; Christophe Najem; Bruno Mourvillier; Jean Christophe Lucet; Bernard Régnier; Michel Wolff; Florence Tubach
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

Review 7.  Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries.

Authors:  Maria D Van Kerkhove; Siddhivinayak Hirve; Artemis Koukounari; Anthony W Mounts
Journal:  Influenza Other Respir Viruses       Date:  2013-01-21       Impact factor: 4.380

8.  Seroepidemiologic investigation of an outbreak of pandemic influenza A H1N1 2009 aboard a US Navy vessel--San Diego, 2009.

Authors:  Christina B Khaokham; Monica Selent; Fleetwood V Loustalot; Shauna Mettee Zarecki; Douglas Harrington; Eileen Hoke; Dennis J Faix; Ryan Ortiguerra; Bryan Alvarez; Nathaniel Almond; Kellie McMullen; Betsy Cadwell; Timothy M Uyeki; Patrick J Blair; Stephen H Waterman
Journal:  Influenza Other Respir Viruses       Date:  2013-03-17       Impact factor: 4.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.